An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) treatments by helping infected cells die a gentler death, Johns Hopkins Medicine investigators report, based on mouse-model research of the lung-damaging disease. Findings from the study, funded by the National Institutes of Health and published March 27 in Nature Communications, could lead to more effective and less onerous therapies that reduce lung damage in TB…
Continue Reading
News Source: www.sciencedaily.com

